Emergency Prevention System for Transboundry Animals and Plant Pest Diseases (EMPRES) From 19 to 21 January 2011, Rift Valley Fever Vaccine Development, Progress and Constraints, an international expert workshop organized by the Food and Agriculture Organization of the United Nations (FAO) and the Central Veterinary Institute of Wageningen University and Research Centre (CVI-WUR) convened 34 leading experts and policy makers in Rift Valley fever (RVF) virology, epidemiology and vaccine development. The main objective of the meeting was to gain consensus on the desired features of novel veterinary Rift Valley fever virus vaccines and to discuss how incentives can be established to make sure that these vaccines come to market. The views from international organizations and industry on the current and future control of RVF were presented and the stages of development of candidate vaccines were reported.
The desired characteristics of vaccines for application in different areas of the world were debated as well as the advantage of applying DIVA vaccines. List of documents. Creation of a non-spreading Rift Valley fever virus -- Kortekaas et al., 10.1128/JVI.00841-11 -- The Journal of Virology. + Author Affiliations Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic bunyavirus of the phlebovirus genus and a serious human and veterinary pathogen. RVFV contains a three-segmented RNA genome, which is comprised of the large (L), medium (M) and small (S) segment. The proteins that are essential for genome replication are encoded by the L and S segments, whereas the structural glycoproteins are encoded by the M segment. We have produced BHK replicon cell lines (BHK-Rep) that maintain replicating L and S genome segments. Transfection of BHK-Rep cells with a plasmid encoding the structural glycoproteins results in the efficient production of RVFV replicon particles (RRPs).
To facilitate monitoring of infection, the NSs gene was replaced by the eGFP gene. ↵*Corresponding author. Copyright © 2011, American Society for Microbiology and/or the Listed Authors/Institutions. GF-TADs meeting - January 2011 - RIFT VALLEY FEVER VACCINE DEVELOPMENT, PROGRESS AND CONSTRAINTS. 2157-7560-2-121. Help for Rift Valley fever - The Pulse - Health - September 1, 2011 - Chico News.